Ivosidenib in relapsed or refractory acute myeloid leukemia: a profile of its use in the USA (vol 35, pg 160, 2019)

被引：0
|
作者：
McCafferty, Emma H. [1 ]
Lyseng-Williamson, Katherine Ann [1 ]
机构：
[1] Springer, Private Bag 65901,Mairangi Bay, Auckland 0754, New Zealand
来源：
DRUGS & THERAPY PERSPECTIVES | 2019年 / 35卷 / 09期
关键词：
D O I：
10.1007/s40267-019-00645-5
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
The original article has been corrected.
引用
收藏
页码：460 / 460
页数：1
相关论文
共 50 条
  • [1] Ivosidenib in relapsed or refractory acute myeloid leukemia: a profile of its use in the USA
    McCafferty, Emma H.
    Lyseng-Williamson, Katherine A.
    DRUGS & THERAPY PERSPECTIVES, 2019, 35 (04) : 160 - 166
  • [2] Ivosidenib in relapsed or refractory acute myeloid leukemia: a profile of its use in the USA
    Emma H. McCafferty
    Katherine A. Lyseng-Williamson
    Drugs & Therapy Perspectives, 2019, 35 : 160 - 166
  • [3] Correction to: Ivosidenib in relapsed or refractory acute myeloid leukemia: a profile of its use in the USA
    Emma H. McCafferty
    Katherine Ann Lyseng-Williamson
    Drugs & Therapy Perspectives, 2019, 35 : 460 - 460
  • [4] Ivosidenib to treat adult patients with relapsed or refractory acute myeloid leukemia
    Pasquier, F.
    Lecuit, M.
    Broutin, S.
    Saada, V
    Jeanson, A.
    Penard-Lacronique, V
    de Botton, S.
    DRUGS OF TODAY, 2020, 56 (01) : 21 - 35
  • [5] Ivosidenib for the treatment of relapsed or refractory acute myeloid leukemia with an IDH1 mutation
    Pasquier, Florence
    Chahine, Claude
    Marzac, Christophe
    de Botton, Stephane
    EXPERT REVIEW OF PRECISION MEDICINE AND DRUG DEVELOPMENT, 2020, 5 (06): : 429 - 438
  • [6] Metreleptin in lipodystrophy: a profile of its use (vol 35, pg 201, 2019)
    Deeks, Emma
    DRUGS & THERAPY PERSPECTIVES, 2019, 35 (10) : 527 - 527
  • [7] FDA Approval Summary: Ivosidenib for Relapsed or Refractory Acute Myeloid Leukemia with an Isocitrate Dehydrogenase-1 Mutation
    Norsworthy, Kelly J.
    Luo, Lola
    Hsu, Vicky
    Gudi, Ramadevi
    Dorff, Sarah E.
    Przepiorka, Donna
    Deisseroth, Albert
    Shen, Yuan-Li
    Sheth, Christopher M.
    Charlab, Rosane
    Williams, Gene M.
    Goldberg, Kirsten B.
    Farrell, Ann T.
    Pazdur, Richard
    CLINICAL CANCER RESEARCH, 2019, 25 (11) : 3205 - 3209
  • [8] Ivosidenib in Chinese patients with relapsed or refractory isocitrate dehydrogenase 1 mutated acute myeloid leukemia: a registry study
    Sun, Mingyuan
    Yin, Qingsong
    Liang, Yang
    Chang, Chunkang
    Zheng, Jing
    Li, Jian
    Ji, Chunyan
    Qiu, Huiying
    Li, Junmin
    Gong, Yuping
    Luo, Sheng
    Zhang, Yan
    Chen, Rumei
    Shen, Zhenwei
    Yue, Zenglian
    Wang, Siyuan
    Shi, Qingmei
    Yang, Jason
    Jin, Jie
    Wang, Jianxiang
    BLOOD SCIENCE, 2024, 6 (03): : e00196
  • [9] USE OF HYPOMETHYLATING AGENTS IN RELAPSED/REFRACTORY PEDIATRIC ACUTE MYELOID LEUKEMIA
    Sabnis, Himalee
    Raikar, Sunil
    Bennett, Anna
    MacDonald, Kelly
    Watkins, Benjamin
    Woods, William
    Keller, Frank
    PEDIATRIC BLOOD & CANCER, 2021, 68 : S52 - S53
  • [10] Clinical pharmacokinetics and pharmacodynamics of ivosidenib in Chinese patients with relapsed or refractory IDH1-mutated acute myeloid leukemia
    Yue, Zenglian
    Pan, Chaohsuan
    Wang, Siyuan
    Tse, Archie N.
    Sheng, Yucheng
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2024, 80 (01) : 105 - 113
12345